DK3805248T5 - Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf - Google Patents

Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf Download PDF

Info

Publication number
DK3805248T5
DK3805248T5 DK20200642.5T DK20200642T DK3805248T5 DK 3805248 T5 DK3805248 T5 DK 3805248T5 DK 20200642 T DK20200642 T DK 20200642T DK 3805248 T5 DK3805248 T5 DK 3805248T5
Authority
DK
Denmark
Prior art keywords
antibodies
procedure
concentration
therapeutic products
therapeutic
Prior art date
Application number
DK20200642.5T
Other languages
Danish (da)
English (en)
Other versions
DK3805248T3 (da
Inventor
Charles Matthew Winter
Original Assignee
Novartis Ag
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35996499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3805248(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Genentech Inc filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3805248T3 publication Critical patent/DK3805248T3/da
Publication of DK3805248T5 publication Critical patent/DK3805248T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/16—Feed pretreatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/16—Flow or flux control
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
DK20200642.5T 2004-09-09 2005-09-08 Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf DK3805248T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60909204P 2004-09-09 2004-09-09
US11/220,362 US20060051347A1 (en) 2004-09-09 2005-09-06 Process for concentration of antibodies and therapeutic products thereof
EP10009914.2A EP2292636B9 (en) 2004-09-09 2005-09-08 Process for concentration of antibodies and therapeutic products thereof

Publications (2)

Publication Number Publication Date
DK3805248T3 DK3805248T3 (da) 2023-04-03
DK3805248T5 true DK3805248T5 (da) 2023-04-24

Family

ID=35996499

Family Applications (5)

Application Number Title Priority Date Filing Date
DK20200642.5T DK3805248T5 (da) 2004-09-09 2005-09-08 Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf
DK22178117.2T DK4108259T3 (da) 2004-09-09 2005-09-08 Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf
DK22178156.0T DK4104859T3 (da) 2004-09-09 2005-09-08 Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf
DK10009914.2T DK2292636T3 (da) 2004-09-09 2005-09-08 Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf
DK05806393.4T DK1786830T3 (en) 2004-09-09 2005-09-08 Process for the concentration of antibodies and therapeutic products thereof

Family Applications After (4)

Application Number Title Priority Date Filing Date
DK22178117.2T DK4108259T3 (da) 2004-09-09 2005-09-08 Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf
DK22178156.0T DK4104859T3 (da) 2004-09-09 2005-09-08 Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf
DK10009914.2T DK2292636T3 (da) 2004-09-09 2005-09-08 Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf
DK05806393.4T DK1786830T3 (en) 2004-09-09 2005-09-08 Process for the concentration of antibodies and therapeutic products thereof

Country Status (32)

Country Link
US (6) US20060051347A1 (https=)
EP (5) EP1786830B1 (https=)
JP (2) JP5210633B2 (https=)
KR (2) KR20070109975A (https=)
CN (3) CN104961797B (https=)
AR (1) AR050641A1 (https=)
AU (1) AU2005285243C1 (https=)
BR (1) BRPI0515649B8 (https=)
CA (1) CA2577317C (https=)
DK (5) DK3805248T5 (https=)
EC (1) ECSP077282A (https=)
ES (5) ES2975166T3 (https=)
FI (4) FI3805248T3 (https=)
GT (1) GT200500254A (https=)
HU (4) HUE067662T2 (https=)
IL (2) IL181372A (https=)
LT (4) LT3805248T (https=)
MA (1) MA28991B1 (https=)
MX (2) MX342788B (https=)
MY (2) MY150549A (https=)
NO (1) NO333660B1 (https=)
NZ (1) NZ553239A (https=)
PE (1) PE20060816A1 (https=)
PL (5) PL4108259T3 (https=)
PT (5) PT2292636T (https=)
RU (1) RU2390524C2 (https=)
SG (1) SG177161A1 (https=)
SI (5) SI1786830T1 (https=)
TN (1) TNSN07069A1 (https=)
TW (1) TWI372630B (https=)
WO (1) WO2006031560A2 (https=)
ZA (1) ZA200701626B (https=)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
EP1713904B1 (en) 2004-01-30 2016-06-29 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulfatase a
EP1765294B1 (en) 2004-05-12 2008-09-24 Baxter International Inc. Nucleic acid microspheres, production and delivery thereof
CA2566199C (en) 2004-05-12 2013-10-22 Baxter International Inc. Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
CN101415482B (zh) * 2006-03-31 2015-04-15 金克克国际有限公司 用于化合物分离的切向流动过滤设备、系统和方法
HUE042402T2 (hu) 2006-04-04 2019-06-28 Chiesi Farm Spa Eljárás polipeptid töményítésére
RU2476442C2 (ru) 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
CN101754977B (zh) * 2007-07-17 2013-07-17 弗·哈夫曼-拉罗切有限公司 可变切向流过滤
US20100249384A1 (en) * 2007-11-29 2010-09-30 Stefan Hepbildikler Immunoglobulin aggregates
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
AU2009236305B2 (en) * 2008-04-15 2014-04-10 Grifols Therapeutics Inc. Two-stage ultrafiltration/diafiltration
CN102124027B (zh) * 2008-05-15 2015-01-21 温氏健康有限公司 产生富含分泌型免疫球蛋白的乳组分的方法
JP2012511531A (ja) * 2008-12-09 2012-05-24 エフ．ホフマン−ラ ロシュ アーゲー 賦形剤不含抗体溶液を得るための方法
WO2010090864A2 (en) * 2009-01-21 2010-08-12 Smartflow Technologies, Inc. Optimization of separation for viscous suspensions
AU2010221156A1 (en) * 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
EP2411125B1 (en) * 2009-03-24 2019-05-08 Wyeth LLC Membrane evaporation for generating highly concentrated protein therapeutics
TWI445714B (zh) * 2009-05-27 2014-07-21 Baxter Int 產製用於皮下使用之高濃度免疫球蛋白製備物之方法
CN102574912B (zh) 2009-09-29 2014-12-24 弗·哈夫曼-拉罗切有限公司 缓冲溶质的过滤前调节
BR112012004054B1 (pt) 2009-10-01 2021-09-08 F. Hoffmann-La Roche Ag Método para produzir um anticorpo anti-her2
WO2011095543A1 (en) 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US10336992B2 (en) 2011-07-08 2019-07-02 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase A
HRP20250713T8 (hr) * 2011-09-01 2025-10-24 Chugai Seiyaku Kabushiki Kaisha Postupak priprave pripravka koji sadrži visoko koncentrirana protutijela ultrafiltriranjem
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CN104955479A (zh) * 2012-12-28 2015-09-30 诺和诺德股份有限公司 高温死端抗体过滤
CN112126634A (zh) 2013-01-09 2020-12-25 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法
DE102013001628A1 (de) 2013-01-30 2014-07-31 Fresenius Medical Care Deutschland Gmbh Verfahren zur Bereitstellung eines Konzentrats
EP4218991A1 (en) 2014-05-13 2023-08-02 Amgen Inc. Process control systems and methods for use with filters and filtration processes
WO2015195453A2 (en) * 2014-06-16 2015-12-23 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
EP4144434B1 (en) * 2014-06-16 2024-04-17 EMD Millipore Corporation Single-pass filtration systems and processes
EP2957335B1 (en) * 2014-06-16 2020-05-27 EMD Millipore Corporation Single-pass filtration systems and processes
US10207225B2 (en) 2014-06-16 2019-02-19 Emd Millipore Corporation Single-pass filtration systems and processes
ES2742704T3 (es) 2014-06-25 2020-02-17 Emd Millipore Corp Elementos, módulos y sistemas de filtro compactos, enrollados en espiral
SG11201508664VA (en) 2014-08-29 2016-03-30 Emd Millipore Corp Single Pass Tangential Flow Filtration Systems and Tangential Flow Filtration Systems withRecirculation of Retentate
CN108325391B (zh) 2014-08-29 2021-05-18 Emd 密理博公司 过滤液体进料的方法
WO2016065181A1 (en) 2014-10-23 2016-04-28 Amgen Inc. Reducing viscosity of pharmaceutical formulations
ES2988823T3 (es) 2014-12-03 2024-11-21 Csl Behring Ag Producto farmacéutico con mayor estabilidad que comprende inmunoglobulinas
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
MX2018003298A (es) * 2015-09-22 2018-06-20 Pfizer Metodo para preparar una formulacion de proteinas terapeuticas y formulacion de anticuerpos producida por tal metodo.
CA3023486C (en) 2016-06-09 2022-03-29 Emd Millipore Corporation Radial-path filter elements, systems and methods of using same
EP3500589B1 (en) * 2016-08-16 2022-05-04 Genzyme Corporation Methods of processing a fluid including a recombinant therapeutic protein and use thereof
WO2018033482A1 (en) * 2016-08-17 2018-02-22 Boehringer Ingelheim International Gmbh Process for the preparation of highly concentrated liquid formulations containing biomolecules
PT3528787T (pt) 2016-10-21 2026-03-11 Amgen Inc Formulações farmacêuticas e métodos para produzir as mesmas
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
CN107952280A (zh) * 2017-11-28 2018-04-24 安徽东方帝维生物制品股份有限公司 一种兽用疫苗无菌超滤浓缩装置及方法
KR102754228B1 (ko) * 2017-12-27 2025-01-14 (주)셀트리온 투석 여과 방법
MX2020010724A (es) * 2018-04-12 2020-11-06 Amgen Inc Metodos para preparar composiciones proteicas estables.
TWI846694B (zh) * 2018-05-04 2024-07-01 美商健臻公司 具有過濾系統的灌注式生物反應器
MA53272A (fr) * 2018-08-10 2021-11-17 Amgen Inc Procédé de préparation d'une formulation pharmaceutique d'anticorps
US12103949B2 (en) * 2018-08-14 2024-10-01 Bristol-Myers Squibb Company Protein recovery
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
JP2022520793A (ja) * 2019-02-15 2022-04-01 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 自動バイオ製造システム、施設、及びプロセス
MY191879A (en) * 2019-07-31 2022-07-18 Catalent Uk Swindon Zydis Ltd Density flow meter for pharmaceutical formulation dosing
CN111018968B (zh) * 2019-12-16 2021-07-27 兴盟生物医药(苏州)有限公司 一种通过超滤浓缩制备高浓度抗体制剂的方法
JP7338527B2 (ja) * 2020-03-19 2023-09-05 東レ株式会社 体液検体中のアレルゲン特異的ＩｇＥ抗体の検出方法
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
CN116406369A (zh) * 2020-10-05 2023-07-07 百时美施贵宝公司 用于浓缩蛋白质的方法
EP4243966A1 (en) 2020-11-23 2023-09-20 Abec, Inc. Filtration systems,components and methods
CA3210568A1 (en) * 2021-03-08 2022-09-15 Boehringer Ingelheim International Gmbh Systems and methods for single pass counter current diafiltration
CN114014929B (zh) * 2021-11-04 2022-07-19 江苏荃信生物医药股份有限公司 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法
JP2025507625A (ja) 2022-02-25 2025-03-21 アムジエン・インコーポレーテツド 高濃度の液体原薬を調製する方法
CN115261193A (zh) * 2022-05-31 2022-11-01 利穗科技(苏州)有限公司 一种生物制品浓缩系统及其工艺
IL318205A (en) * 2022-07-12 2025-03-01 Beigene Switzerland Gmbh Method for preparing a highly concentrated solution of anti-PD1 antibody using ultrafiltration/diafiltration (UF/DF)
CN115873064A (zh) * 2022-09-27 2023-03-31 英脉生物医药(杭州)有限公司 高浓度蛋白样品的制备装置及方法
EP4702122A1 (en) * 2023-04-25 2026-03-04 Enzene Biosciences Limited In line cleaning in place process for alternating tangential flow filter
US12030959B1 (en) 2023-07-05 2024-07-09 Genentech, Inc. Anti-IgE antibody therapy for multiple food allergies
CA3237624A1 (en) 2023-07-28 2025-04-24 Genentech, Inc. NEW USES FOR OMALIZUMAB
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5625616B2 (https=) 1973-10-08 1981-06-13
FR2459619B1 (fr) 1979-06-26 1983-07-29 Agronomique Inst Nat Rech Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ZA847349B (en) * 1983-10-05 1985-04-24 Solco Basel Ag Process for the preparation of a biologically active extract
US4786501A (en) * 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
US4756696A (en) 1985-12-06 1988-07-12 Amp Incorporated Solder joint inspection feature for surface mount connectors
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
JPS6485829A (en) 1987-09-29 1989-03-30 Aisin Aw Co Transmission for four-wheel drive vehicle
JPH01268646A (ja) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
GB2218703B (en) 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
AU4803890A (en) 1988-12-15 1990-07-10 Invitron Corporation Use of basic amino acids to solubilize immunoglobulins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
NL9001650A (nl) 1990-07-19 1992-02-17 Ver Coop Melkind Werkwijze voor de bereiding van een melkeiwit-isolaat.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5256294A (en) 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
JP2916947B2 (ja) 1990-11-28 1999-07-05 興和株式会社 Ｃｐｂ―ｉの安定化方法及び製剤組成物
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JP2907603B2 (ja) * 1991-09-09 1999-06-21 雪印乳業株式会社 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5707678A (en) 1995-04-12 1998-01-13 Galagen Inc. Method for microfiltration of milk or colostral whey
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2434840T3 (es) * 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE19543737A1 (de) 1995-11-24 1997-05-28 Hoechst Ag Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
AU4589397A (en) 1997-09-22 1999-04-12 Sepragen Corporation Sequential separation of whey proteins and formulations thereof
RU2140287C1 (ru) * 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Способ получения альбумина
AU6405899A (en) 1998-10-26 2000-05-15 Galagen, Inc. Soy and immunoglobulin compositions
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
WO2001003515A1 (en) 1999-07-07 2001-01-18 New Zealand Co-Operative Dairy Company Limited Method of obtaining protein isolates and concentrates from colostrum
CZ20021186A3 (cs) 1999-10-04 2002-11-13 Chiron Corporation Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
EP1450847B1 (en) * 2001-11-13 2010-09-29 Genentech, Inc. APO2 ligand/ TRAIL formulations and uses thereof
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
CN1671741A (zh) * 2002-06-21 2005-09-21 拜奥根Idec公司 浓缩抗体的缓冲剂制剂及其使用方法
JP4500683B2 (ja) * 2002-11-01 2010-07-14 バイエル・ヘルスケア・エルエルシー 巨大分子濃縮方法
GB0229444D0 (en) 2002-12-18 2003-01-22 Royal Free Hampstead Nhs Trust Diagnostic method and assay kit
AU2003261387A1 (en) * 2003-02-24 2004-09-17 Gtc Biotherapeutics, Inc. Methods of tangential flow filtration and an apparatus therefore
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
US20070244305A1 (en) 2004-01-30 2007-10-18 Suomen Punainen Risti Veripalvelu Process for The Manufacture of Virus Safe Immunoglobulin
WO2005082109A2 (en) 2004-02-26 2005-09-09 Massachusetts Institute Of Technology Solution additives for the attenuation of protein aggregation
US8471757B2 (en) 2004-08-19 2013-06-25 Electronic Navigation Research Institute, An Independent Administrative Institution Device using dielectric lens
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP6044754B2 (ja) 2012-01-19 2016-12-14 株式会社ジェイテクト クラッチプレートおよびその製造方法
WO2019035815A1 (en) 2017-08-16 2019-02-21 O&M Halyard International Unlimited Company METHOD AND SYSTEM FOR FASTENING ATTACHES IN A METHOD FOR MANUFACTURING FACIAL MASKS

Also Published As

Publication number Publication date
DK1786830T3 (en) 2015-01-19
SI4104859T1 (sl) 2024-08-30
CN104961797A (zh) 2015-10-07
SI2292636T1 (sl) 2024-02-29
CN101056885B (zh) 2015-08-26
MX342788B (es) 2016-10-12
TNSN07069A1 (en) 2008-06-02
DK4108259T3 (da) 2024-03-11
EP3805248A3 (en) 2021-07-14
JP2008512473A (ja) 2008-04-24
US20230074486A1 (en) 2023-03-09
FI4108259T3 (fi) 2024-09-10
MX2007002812A (es) 2007-05-16
CA2577317A1 (en) 2006-03-23
EP4104859A1 (en) 2022-12-21
HUE067296T2 (hu) 2024-10-28
TW200612989A (en) 2006-05-01
KR20120135530A (ko) 2012-12-14
EP4104859B1 (en) 2024-04-17
JP2012097086A (ja) 2012-05-24
ZA200701626B (en) 2008-10-29
EP4108259A1 (en) 2022-12-28
IL216851A0 (en) 2012-01-31
BRPI0515649B1 (pt) 2021-10-13
US20210095050A1 (en) 2021-04-01
AU2005285243B2 (en) 2012-03-08
AR050641A1 (es) 2006-11-08
EP1786830B1 (en) 2014-11-12
FI3805248T3 (fi) 2023-04-21
TWI372630B (en) 2012-09-21
EP2292636A3 (en) 2013-05-01
PT3805248T (pt) 2023-04-05
SI4108259T1 (sl) 2024-04-30
ES2983099T3 (es) 2024-10-22
DK2292636T3 (da) 2024-01-15
DK4104859T3 (da) 2024-07-08
FI4104859T3 (fi) 2024-07-16
BRPI0515649B8 (pt) 2021-11-03
US11767370B2 (en) 2023-09-26
PL3805248T3 (pl) 2023-05-22
MY150549A (en) 2014-01-30
NZ553239A (en) 2009-11-27
WO2006031560A3 (en) 2006-08-24
EP2292636B1 (en) 2023-10-18
HUE061899T2 (hu) 2023-08-28
ES2968070T3 (es) 2024-05-07
AU2005285243A1 (en) 2006-03-23
WO2006031560A2 (en) 2006-03-23
PL2292636T3 (pl) 2024-03-11
US12371510B2 (en) 2025-07-29
KR101528970B1 (ko) 2015-06-15
HK1101249A1 (en) 2007-10-12
ECSP077282A (es) 2007-03-29
LT2292636T (lt) 2024-01-10
RU2007110534A (ru) 2008-10-20
PT4104859T (pt) 2024-07-02
AU2005285243C1 (en) 2012-10-25
SI1786830T1 (sl) 2015-03-31
PT1786830E (pt) 2015-02-05
JP5210633B2 (ja) 2013-06-12
HUE067662T2 (hu) 2024-11-28
SI3805248T1 (sl) 2023-05-31
EP1786830A2 (en) 2007-05-23
PT4108259T (pt) 2024-03-07
ES2528541T3 (es) 2015-02-10
KR101528970B9 (ko) 2022-12-09
US20060051347A1 (en) 2006-03-09
LT4108259T (lt) 2024-04-10
US20090214522A1 (en) 2009-08-27
DK3805248T3 (da) 2023-04-03
CN101056885A (zh) 2007-10-17
US10370456B2 (en) 2019-08-06
EP4108259B1 (en) 2024-01-03
CN102911268A (zh) 2013-02-06
JP5426641B2 (ja) 2014-02-26
CN104961797B (zh) 2020-12-25
KR20070109975A (ko) 2007-11-15
HUE065025T2 (hu) 2024-04-28
PE20060816A1 (es) 2006-09-02
PL4108259T3 (pl) 2024-05-13
HK1215869A1 (zh) 2016-09-23
EP3805248A2 (en) 2021-04-14
GT200500254A (es) 2006-08-02
PL1786830T3 (pl) 2015-05-29
PL4104859T3 (pl) 2024-08-26
ES2942574T3 (es) 2023-06-02
PT2292636T (pt) 2024-01-09
US20070237762A1 (en) 2007-10-11
EP3805248B1 (en) 2023-01-18
EP2292636B9 (en) 2024-01-03
BRPI0515649A (pt) 2008-07-29
IL181372A0 (en) 2007-07-04
EP2292636A2 (en) 2011-03-09
SG177161A1 (en) 2012-01-30
LT4104859T (lt) 2024-07-10
LT3805248T (lt) 2023-04-25
ES2975166T3 (es) 2024-07-03
NO20071432L (no) 2007-03-16
FI2292636T3 (fi) 2024-01-12
US20140370003A1 (en) 2014-12-18
NO333660B1 (no) 2013-08-05
MY162525A (en) 2017-06-15
CA2577317C (en) 2016-04-26
IL181372A (en) 2012-01-31
MA28991B1 (fr) 2007-11-01
RU2390524C2 (ru) 2010-05-27

Similar Documents

Publication Publication Date Title
DK3805248T3 (da) Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf
DK3345927T5 (da) Humant monoklonalt antistof Human CD134 (OX40) og fremgangsmåder til frembringelse og anvendelse deraf
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DK1641832T3 (da) Fremgangsmåde til fremstilling af fiberholdig pektin og produkter og anvendelser heraf
DK1679058T3 (da) Farmaceutisk sammensætning til behandling af kardiovaskulære og cerebrovaskulære sygdomme
DK1756544T3 (da) Diagnoseindretninger indeholdende fluider og fremgangsmåder til fremstilling
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK1844074T3 (da) Humane antistoffer og proteiner
NO20033387L (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
DK1788881T3 (da) Fremgangsmåder og produkter til brødfremstilling
DK1740197T3 (da) Prolyl-endopeptidease (PEP) og glutamin-endoprotease til behandlingen af cøliaki
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1663298T3 (da) Anvendelse af prolinspecifikke endoproteaser til hydrolyse af peptider og proteiner
DK1877090T3 (da) Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
DK1965763T3 (da) Stabile enzympræparater og fremgangsmåder til anvendelse heraf
DK2144555T3 (da) Indretning og fremgangsmåde til transkutan bestemmelse af blodgasser
DK1922309T3 (da) N-phenyl-2-pyrimidin-aminderivater og fremgangsmåde til fremstillingen deraf
DK1596868T3 (da) Fremgangsmåde til behandling af hjertesvigt og medikament dertil
DK1862158T3 (da) Farmaceutisk sammensætning til behandling af depression og fremgangsmåde til fremstilling deraf
DK1768489T3 (da) Apparat og fremgangsmåde til destruktion af vegetation
DK1817055T3 (da) Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf
IS7572A (is) Aðferð og efni til lækninga
DK1589973T4 (da) Formulering og fremgangsmåder til behandling af thrombocytæmi